Online ISSN: 2577-5669
-
Development of Telmisartan 40 mg Tablets with Improved Bioavailability Using Solid Dispersion Technique
Volume 17 | Issue 1
-
Design and optimization of Glibenclamide -nanoemulsion Technology for Enhanced Drug Delivery
Volume 17 | Issue 1
-
Formulation and evaluation of nano emulsion of aceclofenac (100mg) for enhanced solubility and dissolution rate
Volume 17 | Issue 1
-
Development of Controlled Release Matrix Tablets using Natural Polymers
Volume 17 | Issue 1
-
Evolution of Drug Regulatory Guidelines in the Era of Globalization
Volume 17 | Issue 1
Myelodysplastic syndromes and acute myeloid leukemia: Medical management and dental considerations
Main Article Content
Abstract
The World Health Organization explained myelodysplastic syndromes as clonal hematopoietic disorders characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. Myelodysplastic syndromes have a high probability of transformation into acute myeloid leukemia. Dental care professionals should have a basic understanding of myelodysplastic syndromes to help support patients and deliver safe dental treatment.
